Synthetic Antibacterial Peptide Exhibits Synergy with Oxacillin against MRSA

Area of Science:

• Microbiology
• Pharmacology
• Drug Discovery

Background:

• Antimicrobial resistance (AMR) poses a significant global health crisis.
• Existing treatments often lack specificity, leading to collateral damage to host flora.
• Targeted approaches are needed to potentiate existing antibiotics against resistant pathogens.

Purpose of the Study:

• To develop a novel peptide-antibiotic combination therapy for antimicrobial resistance.
• To create a molecule that potentiates narrow-spectrum antibiotics against specific resistant bacteria.
• To evaluate the efficacy of the peptide ASU014 in combination with oxacillin against MRSA.

Main Methods:

• Design and synthesis of a peptide (ASU014) comprising S. aureus binding and inhibitory domains on a branched scaffold.
• In vitro testing of ASU014 and oxacillin for synergistic activity against MRSA.
• In vivo evaluation of the combination therapy in a MRSA skin infection model.

Main Results:

• ASU014 demonstrated modest intrinsic activity against S. aureus.
• Significant synergy was observed between ASU014 and oxacillin against MRSA.
• The combination therapy was effective both in vitro and in a preclinical MRSA skin infection model.

Conclusions:

• The peptide ASU014 shows promise as an adjunct therapy to potentiate oxacillin against MRSA.
• Low concentrations of ASU014 and sub-inhibitory concentrations of oxacillin are effective, suggesting a favorable therapeutic window.
• ASU014 is a potential candidate for further medicinal chemistry optimization to combat AMR infections.